

# Catherine Alix-Panabières

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5459276/publications.pdf>

Version: 2024-02-01

121  
papers

12,731  
citations

36271

51  
h-index

24232

110  
g-index

127  
all docs

127  
docs citations

127  
times ranked

13213  
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of cancer metastasis: past, present and future. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 21-28.	1.7	9
2	Abstract P2-01-12: Detection of circulating tumor cells in cerebrospinal fluid for patients with suspected breast cancer leptomeningeal metastases: A prospective study. <i>Cancer Research</i> , 2022, 82, P2-01-12-P2-01-12.	0.4	0
3	Liquid Biopsy to Catch the Epigenetic Changes in Endometrial Cancer. <i>Clinical Chemistry</i> , 2022, , .	1.5	0
4	Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade. <i>British Journal of Cancer</i> , 2022, 127, 800-810.	2.9	38
5	Looking at Thyroid Cancer from the Tumor-Suppressor Genes Point of View. <i>Cancers</i> , 2022, 14, 2461.	1.7	0
6	Liquid Biopsy: How to Embrace Perfection?. , 2022, 9, 54-56, 59.		0
7	Efficacy of Circulating Tumor Cell CountâDriven vs Clinician-Driven First-line Therapy Choice in Hormone ReceptorâPositive, ERBB2-Negative Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 34.	3.4	92
8	Photonic Technologies for Liquid Biopsies: Recent Advances and Open Research Challenges. <i>Laser and Photonics Reviews</i> , 2021, 15, .	4.4	10
9	Liquid Biopsies: Photonic Technologies for Liquid Biopsies: Recent Advances and Open Research Challenges ( <i>Laser Photonics Rev.</i> 15(1)/2021). <i>Laser and Photonics Reviews</i> , 2021, 15, 2170012.	4.4	3
10	Proficiency Testing to Assess Technical Performance for CTC-Processing and Detection Methods in CANCER-ID. <i>Clinical Chemistry</i> , 2021, 67, 631-641.	1.5	25
11	Identifying key questions in the ecology and evolution of cancer. <i>Evolutionary Applications</i> , 2021, 14, 877-892.	1.5	58
12	Selective treatment pressure in colon cancer drives the molecular profile of resistant circulating tumor cell clones. <i>Molecular Cancer</i> , 2021, 20, 30.	7.9	30
13	Group phenotypic composition in cancer. <i>ELife</i> , 2021, 10, .	2.8	18
14	Liquid Biopsy: From Discovery to Clinical Application. <i>Cancer Discovery</i> , 2021, 11, 858-873.	7.7	407
15	Does Cancer Biology Rely on Parrondoâs Principles?. <i>Cancers</i> , 2021, 13, 2197.	1.7	7
16	<i>Liquid biopsy</i>: from discovery to clinical implementation. <i>Molecular Oncology</i> , 2021, 15, 1617-1621.	2.1	9
17	Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study. <i>Cancers</i> , 2021, 13, 2966.	1.7	11
18	Is There One Key Step in the Metastatic Cascade?. <i>Cancers</i> , 2021, 13, 3693.	1.7	26

#	ARTICLE	IF	CITATIONS
19	Current Applications and Discoveries Related to the Membrane Components of Circulating Tumor Cells and Extracellular Vesicles. <i>Cells</i> , 2021, 10, 2221.	1.8	5
20	Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer. <i>Clinical Chemistry</i> , 2021, 67, 1503-1512.	1.5	38
21	On the need for integrating cancer into the One Health perspective. <i>Evolutionary Applications</i> , 2021, 14, 2571-2575.	1.5	9
22	Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9714.	1.8	20
23	Epithelial-to-Mesenchymal Plasticity in Circulating Tumor Cell Lines Sequentially Derived from a Patient with Colorectal Cancer. <i>Cancers</i> , 2021, 13, 5408.	1.7	18
24	Circulating tumor cell as the functional aspect of liquid biopsy to understand the metastatic cascade in solid cancer. <i>Molecular Aspects of Medicine</i> , 2020, 72, 100816.	2.7	62
25	The Different Facets of Liquid Biopsy: A Kaleidoscopic View. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a037333.	2.9	24
26	Tumor-Associated Release of Prostatic Cells into the Blood after Transrectal Ultrasound-Guided Biopsy in Patients with Histologically Confirmed Prostate Cancer. <i>Clinical Chemistry</i> , 2020, 66, 161-168.	1.5	21
27	Molecular and Functional Characterization of Circulating Tumor Cells: From Discovery to Clinical Application. <i>Clinical Chemistry</i> , 2020, 66, 97-104.	1.5	33
28	Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study. <i>Cancers</i> , 2020, 12, 3002.	1.7	22
29	The Metastatic Cascade as the Basis for Liquid Biopsy Development. <i>Frontiers in Oncology</i> , 2020, 10, 1055.	1.3	27
30	Do malignant cells sleep at night?. <i>Genome Biology</i> , 2020, 21, 276.	3.8	24
31	Epithelial Cell Adhesion Molecule: An Anchor to Isolate Clinically Relevant Circulating Tumor Cells. <i>Cells</i> , 2020, 9, 1836.	1.8	66
32	Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer. <i>Clinical Chemistry</i> , 2020, 66, 1093-1101.	1.5	33
33	Liquid Biopsy to Detect Circulating Tumor Cells: Is It Ready for a Value Proposition in Laboratory Medicine?. <i>Journal of applied laboratory medicine</i> , The, 2020, 5, 1027-1037.	0.6	3
34	High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors. <i>Cells</i> , 2020, 9, 2129.	1.8	26
35	Clinical relevance of liquid biopsy in breast cancer: update in 2020. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 913-919.	1.5	13
36	â€œCirculating Tumor Cells: Finding Rare Events for a Huge Knowledge of Cancer Disseminationâ€• <i>Cells</i> , 2020, 9, 661.	1.8	5

#	ARTICLE	IF	CITATIONS
37	Circulating Tumor Cells as a Marker of Disseminated Disease in Patients with Newly Diagnosed High-Risk Prostate Cancer. <i>Cancers</i> , 2020, 12, 160.	1.7	32
38	Clinical Relevance of Liquid Biopsy in Melanoma and Merkel Cell Carcinoma. <i>Cancers</i> , 2020, 12, 960.	1.7	25
39	The Role of Circulating Tumor Cells in the Metastatic Cascade: Biology, Technical Challenges, and Clinical Relevance. <i>Cancers</i> , 2020, 12, 867.	1.7	63
40	The future of liquid biopsy. <i>Nature</i> , 2020, 579, S9-S9.	13.7	110
41	Circulating Tumor Cell Detection and Polyomavirus Status in Merkel Cell Carcinoma. <i>Scientific Reports</i> , 2020, 10, 1612.	1.6	14
42	Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. <i>EMBO Molecular Medicine</i> , 2020, 12, e11908.	3.3	77
43	Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEC Prospective Study. <i>Clinical Chemistry</i> , 2019, 65, 1267-1275.	1.5	38
44	Never Travel Alone: The Crosstalk of Circulating Tumor Cells and the Blood Microenvironment. <i>Cells</i> , 2019, 8, 714.	1.8	97
45	S100-EPISPOT: A New Tool to Detect Viable Circulating Melanoma Cells. <i>Cells</i> , 2019, 8, 755.	1.8	25
46	Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2019, 11, 852.	1.7	53
47	High Clinical Value of Liquid Biopsy to Detect Circulating Tumor Cells and Tumor Exosomes in Pancreatic Ductal Adenocarcinoma Patients Eligible for Up-Front Surgery. <i>Cancers</i> , 2019, 11, 1656.	1.7	79
48	Detection of Androgen Receptor Variant 7 (ARV7) mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate Cancer. <i>Cells</i> , 2019, 8, 1067.	1.8	18
49	Tumor-proximal liquid biopsy to improve diagnostic and prognostic performances of circulating tumor cells. <i>Molecular Oncology</i> , 2019, 13, 1811-1826.	2.1	27
50	Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays. <i>Cancers</i> , 2019, 11, 802.	1.7	24
51	Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1357-1366.	1.1	19
52	Liquid biopsy and minimal residual disease – latest advances and implications for cure. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 409-424.	12.5	671
53	CTCs as Liquid Biopsy: Where Are We Now?. , 2019, , .		3
54	Metastasis and the evolution of dispersal. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2019, 286, 20192186.	1.2	12

#	ARTICLE	IF	CITATIONS
55	Les cellules tumorales circulantes comme biopsie liquide du cancer. <i>Revue Francophone Des Laboratoires</i> , 2018, 2018, 75-80.	0.0	0
56	Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients. <i>Clinical Chemistry</i> , 2018, 64, 297-306.	1.5	67
57	Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes. <i>Scientific Reports</i> , 2018, 8, 15931.	1.6	67
58	miRNA-30 Family Members Inhibit Breast Cancer Invasion, Osteomimicry, and Bone Destruction by Directly Targeting Multiple Bone Metastasis-Associated Genes. <i>Cancer Research</i> , 2018, 78, 5259-5273.	0.4	141
59	Chromosomal Aberrations Associated with Sequential Steps of the Metastatic Cascade in Colorectal Cancer Patients. <i>Clinical Chemistry</i> , 2018, 64, 1505-1512.	1.5	18
60	Circulating tumour cells and cell-free DNA in gastrointestinal cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 73-74.	8.2	49
61	Molecular Portrait of Metastasis-Competent Circulating Tumor Cells in Colon Cancer Reveals the Crucial Role of Genes Regulating Energy Metabolism and DNA Repair. <i>Clinical Chemistry</i> , 2017, 63, 700-713.	1.5	67
62	Tumour microenvironment: informing on minimal residual disease in solid tumours. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 325-326.	12.5	40
63	Clinical prospects of liquid biopsies. <i>Nature Biomedical Engineering</i> , 2017, 1, .	11.6	31
64	Characterization of single circulating tumor cells. <i>FEBS Letters</i> , 2017, 591, 2241-2250.	1.3	48
65	Epithelial-mesenchymal plasticity in circulating tumor cells. <i>Journal of Molecular Medicine</i> , 2017, 95, 133-142.	1.7	113
66	Detection of Circulating Plasma Cells in Multiple Myeloma. <i>Clinical Chemistry</i> , 2017, 63, 1797-1798.	1.5	0
67	Here comes the spaser. <i>Nature Materials</i> , 2017, 16, 790-791.	13.3	11
68	EpCAM-Independent Enrichment and Detection of Viable Circulating Tumor Cells Using the EPISPOT Assay. <i>Methods in Molecular Biology</i> , 2017, 1634, 263-276.	0.4	30
69	Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2017, 28, 1923-1933.	0.6	153
70	Early detection of lung cancer based on DNA methylation analysis in sputum and plasma. <i>Translational Cancer Research</i> , 2017, 6, S51-S53.	0.4	2
71	Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. <i>Scientific Reports</i> , 2016, 6, 39736.	1.6	96
72	Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction?. <i>Clinical Chemistry</i> , 2016, 62, 1054-1060.	1.5	87

#	ARTICLE	IF	CITATIONS
73	Functional studies on circulating and disseminated tumor cells in carcinoma patients. <i>Molecular Oncology</i> , 2016, 10, 443-449.	2.1	60
74	Functional Studies on Viable Circulating Tumor Cells. <i>Clinical Chemistry</i> , 2016, 62, 328-334.	1.5	87
75	Liquid biopsy: Potential and challenges. <i>Molecular Oncology</i> , 2016, 10, 371-373.	2.1	67
76	Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. <i>Cancer Discovery</i> , 2016, 6, 479-491.	7.7	1,087
77	Establishment and Characterization of a Cell Line from Human Circulating Colon Cancer Cells. <i>Cancer Research</i> , 2015, 75, 892-901.	0.4	321
78	Frequent expression of PD-1 on circulating breast cancer cells. <i>Molecular Oncology</i> , 2015, 9, 1773-1782.	2.1	303
79	Disseminated tumor cells in bone marrow of cancer patients. , 2015, , 471-477.		0
80	Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1411-1417.	1.5	43
81	Cell lines from circulating tumor cells. <i>Oncoscience</i> , 2015, 2, 815-816.	0.9	27
82	Micrometastasis. , 2015, , 1-5.		0
83	Micrometastasis. , 2015, , 2833-2836.		0
84	Prognostic Relevance of Viable Circulating Tumor Cells Detected by EPISPOT in Metastatic Breast Cancer Patients. <i>Clinical Chemistry</i> , 2014, 60, 214-221.	1.5	102
85	Technologies for detection of circulating tumor cells: facts and vision. <i>Lab on A Chip</i> , 2014, 14, 57-62.	3.1	226
86	Bone marrow as a reservoir for disseminated tumor cells: a special source for liquid biopsy in cancer patients. <i>BoneKey Reports</i> , 2014, 3, 584.	2.7	82
87	Challenges in circulating tumour cell research. <i>Nature Reviews Cancer</i> , 2014, 14, 623-631.	12.8	1,102
88	Real-time Liquid Biopsy in Cancer Patients: Fact or Fiction?. <i>Cancer Research</i> , 2013, 73, 6384-6388.	0.4	376
89	Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. <i>Cancer and Metastasis Reviews</i> , 2013, 32, 179-188.	2.7	218
90	Circulating Tumor Cells: Liquid Biopsy of Cancer. <i>Clinical Chemistry</i> , 2013, 59, 110-118.	1.5	942

#	ARTICLE	IF	CITATIONS
91	Capture of Viable Circulating Tumor Cells in the Liver of Colorectal Cancer Patients. <i>Clinical Chemistry</i> , 2013, 59, 1384-1392.	1.5	182
92	Real-time liquid biopsy: circulating tumor cells versus circulating tumor DNA. <i>Annals of Translational Medicine</i> , 2013, 1, 18.	0.7	24
93	Circulating Epithelial Cells in Patients with Benign Colon Diseases. <i>Clinical Chemistry</i> , 2012, 58, 936-940.	1.5	229
94	Plasticity of disseminating cancer cells in patients with epithelial malignancies. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 673-687.	2.7	192
95	EPISPOT Assay: Detection of Viable DTCs/CTCs in Solid Tumor Patients. <i>Recent Results in Cancer Research</i> , 2012, 195, 69-76.	1.8	149
96	The Potential of Circulating Tumor Cells as a Liquid Biopsy to Guide Therapy in Prostate Cancer. <i>Cancer Discovery</i> , 2012, 2, 974-975.	7.7	35
97	Circulating Tumor Cells and Circulating Tumor DNA. <i>Annual Review of Medicine</i> , 2012, 63, 199-215.	5.0	411
98	Circulating tumor cells in prostate cancer: A potential surrogate marker of survival. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 81, 241-256.	2.0	68
99	Detection methods of circulating tumor cells. <i>Journal of Thoracic Disease</i> , 2012, 4, 446-7.	0.6	33
100	Circulating tumor-derived biomarkers in lung cancer. <i>Journal of Thoracic Disease</i> , 2012, 4, 448-9.	0.6	11
101	Clinical relevance and biology of circulating tumor cells. <i>Breast Cancer Research</i> , 2011, 13, 228.	2.2	126
102	Molecular mechanisms of metastasis. <i>Journal of Surgical Oncology</i> , 2011, 103, 508-517.	0.8	37
103	Micrometastasis. , 2011, , 2297-2300.		0
104	Circulating tumour cells in cancer patients: challenges and perspectives. <i>Trends in Molecular Medicine</i> , 2010, 16, 398-406.	3.5	616
105	Insights into minimal residual disease in cancer patients: Implications for anti-cancer therapies. <i>European Journal of Cancer</i> , 2010, 46, 1189-1197.	1.3	56
106	Detection and Characterization of Disseminated Tumor Cells present in Bone Marrow of Cancer Patients. , 2010, , 103-117.		0
107	Cancer micrometastases. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 339-351.	12.5	625
108	Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. <i>Breast Cancer Research</i> , 2009, 11, R39.	2.2	146

#	ARTICLE	IF	CITATIONS
109	Cell-free Tumor DNA in Blood Plasma As a Marker for Circulating Tumor Cells in Prostate Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 1032-1038.	3.2	221
110	Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance. <i>Breast Cancer Research</i> , 2008, 10, S1.	2.2	70
111	Circulating Tumor Cells and Bone Marrow Micrometastasis. <i>Clinical Cancer Research</i> , 2008, 14, 5013-5021.	3.2	229
112	Identification of Loss of Heterozygosity on Circulating Free DNA in Peripheral Blood of Prostate Cancer Patients: Potential and Technical Improvements. <i>Clinical Chemistry</i> , 2008, 54, 688-696.	1.5	40
113	Current status in human breast cancer micrometastasis. <i>Current Opinion in Oncology</i> , 2007, 19, 558-563.	1.1	78
114	The clinical significance of circulating tumor cells. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 62-63.	4.3	105
115	Detection and Characterization of Putative Metastatic Precursor Cells in Cancer Patients. <i>Clinical Chemistry</i> , 2007, 53, 537-539.	1.5	182
116	Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. <i>Journal of Immunological Methods</i> , 2005, 299, 177-188.	0.6	85
117	Detection of Circulating Prostate-Specific Antigen-Secreting Cells in Prostate Cancer Patients. <i>Clinical Chemistry</i> , 2005, 51, 1538-1541.	1.5	58
118	Dynamics of spontaneous HIV-1 specific and non-specific B-cell responses in patients receiving antiretroviral therapy. <i>Aids</i> , 2002, 16, 1755-1760.	1.0	28
119	Spontaneous Secretion of Immunoglobulins and Anti-HIV-1 Antibodies by in Vivo Activated B Lymphocytes from HIV-1-Infected Subjects: Monocyte and Natural Killer Cell Requirement for in Vitro Terminal Differentiation into Plasma Cells. <i>Clinical Immunology</i> , 2002, 103, 98-109.	1.4	25
120	Critical Issues of Research on Circulating and Disseminated Tumor Cells in Cancer Patients. , 0, , 486-500.		0
121	Circulating tumor cells: moving forward into clinical applications. <i>Precision Cancer Medicine</i> , 0, 3, 4-4.	1.8	14